Premium
UCB (PK) (UCBJY)
USOTC
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance transformation as leading examples of innovation in...
New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis show use of newer anti-epilepsy drugs, access to...
UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company...
UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest step towards UCB goal of extending treatment...
UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR Newswire ATLANTA, Dec. 8, 2014 ATLANTA, Dec. 8, 2014...
UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy -- Primary efficacy and safety...
UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care - Atlanta-based Collaboration Will Explore the Potential of Big Data to Help Inform...
UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES) - 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) - First...
UCB shows strong scientific presence at leading rheumatology meeting -- Data to be presented at the ACR/ARHP Annual Meeting on UCB's marketed product CIMZIA® (certolizumab pegol) and the...
Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB PR Newswire BOSTON and NEW YORK, Nov. 7, 2014 BOSTON and NEW YORK, Nov. 7, 2014 /PRNewswire/...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.17 | -1.17458086537 | 99.61 | 100.43 | 97.64 | 5999 | 98.43160623 | DR |
| 4 | 0.77 | 0.788368997645 | 97.67 | 100.43 | 94.206 | 6965 | 97.1025 | DR |
| 12 | 4.36 | 4.6343537415 | 94.08 | 100.43 | 86.71 | 20293 | 95.26334078 | DR |
| 26 | 22.56 | 29.7311544544 | 75.88 | 100.43 | 74.55 | 16201 | 90.43200455 | DR |
| 52 | 54.758 | 125.355981869 | 43.682 | 100.43 | 43.682 | 17499 | 75.70496611 | DR |
| 156 | 42.07 | 74.6318963988 | 56.37 | 100.43 | 32.82 | 20907 | 51.25709616 | DR |
| 260 | 59.2525 | 151.202551834 | 39.1875 | 100.43 | 32.45 | 20026 | 52.52629145 | DR |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
